Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

s and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Discovery Laboratories, ... has been awarded a Phase II Small Business ... $3.0 million from the National Institute of Allergy ... of Health (NIH) to support the development of ... a medical countermeasure to mitigate acute and chronic/late-phase ...
(Date:10/1/2014)... Switzerland (PRWEB) October 01, 2014 ... the quality of the final product. However, while ... regulated, regulatory frameworks such as Good Manufacturing Practices ... the responsibility of the manufacturer to interpret these ... consistent weighing performance quality. METTLER TOLEDO experts have ...
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 The participants ... designs, but to spending their own time adjusting, tweaking ... their complex designs were ready for judging. , “I ... design firm thought leader. “The entries showed a ... the physical characteristics of the print medium and the ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2
... Dec. 30, 2010 Renowned biotech specialist, venture ... predictions for biotech. He sees a dynamic industry writing ... that: favors risk mitigated companies rather than earlier stage ... emerging biotech markets, particularly in Brazil, Chile, China, India, ...
... and pilot whales that are known to have anti-fouling ... are using nanotechnology to create synthetic, chemical-free, anti-bacterial surfaces. ... as S. aureus and E. coli ... devices, lenses and even ship hulls. Conventional methods for ...
... STATION, Dec. 23, 2010 An international team of ... announced a breakthrough that gives a new spin to ... The team has developed an electrically controllable device whose ... the culmination of a 20-year scientific quest involving many ...
Cached Biology Technology:Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011 2Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011 3Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011 4Singapore consortium learns from nature to produce new chemical-free, anti-bacteria plastic 'skins' 2Singapore consortium learns from nature to produce new chemical-free, anti-bacteria plastic 'skins' 3Texas A&M professor helps develop first high-temp spin-field-effect transistor 2Texas A&M professor helps develop first high-temp spin-field-effect transistor 3
(Date:9/30/2014)... HEIGHTS, Ill. (September 30, 2014) People who suffer ... can do to control their asthma besides properly taking ... a new article in the Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), asthma ... examining their lifestyle. The woman described in the Annals ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
(Date:9/29/2014)... WASHINGTON, DC September 29, 2014 -- Plants ... ,commensal, bacteria help the pants extract nutrients and ... preventing pathogens from contaminating fruits and vegetables. Now, ... commensal bacteria inside of seeds; thus ensuring that ... researchers, from the University of Notre Dame, presented ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2Plants prepackage beneficial microbes in their seeds 2
... possibility that life exists beyond Earth. The quest for ... "following the water" turns out to be too general ... possess liquid water is growing faster than can be ... teams, Arizona State University researchers intend to boost extraterrestrial ...
... evolutionary biologists are still debating this question, a ... PLoS ONE, supports the view that the ... thousands of years before the French Revolution, Marx, ... power struggle and their origin had dramatic implications ...
... A UC Riverside-led team of biomedical scientists has found that ... acne and skin infections, can be used to treat ... mental impairment and the most common cause of autism. ... approval of a new clinical trial in Toronto, Canada, that ...
Cached Biology News:NASA picks ASU research team to guide study of search for life 2NASA picks ASU research team to guide study of search for life 3Egalitarian revolution in the Pleistocene? 2Egalitarian revolution in the Pleistocene? 3Egalitarian revolution in the Pleistocene? 4UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
... 96 and PowerPac basic power supply are used ... in agarose gels. This Model 96 cell includes ... UV-transparent gel tray with fluorescent ruler, and a ... and 220-240 V, provides output of 10-300 V, ...
... basic power supply are used for submerged horizontal ... This Model 192 cell includes a buffer tank, ... with fluorescent ruler, and a gel caster. The ... provides output of 10-300 V, 4-400 mA, and ...
... The Sequi-Gen GT and PowerPac 3000 system, ... using a 38 x 30 cm vertical slab ... GT electrophoresis cell, which is capable of separating ... an integral plate chamber (IPC) assembly (IPC and ...
Biology Products: